Metraipolis › archive › dc_c7642d2f577a
Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42459641
- DOI
- 10.3389/fimmu.2026.1841762
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T14:03:19.056Z
- SHA-256 of the archived text
d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3- Stable URL of this page
https://metraipolis.com/documento/dc_c7642d2f577a
How to cite
Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641 — Europe PMC (en), https://europepmc.org/article/MED/42459641 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c7642d2f577a (Metraipolis archive dc_c7642d2f577a, sha256 d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3)
BibTeX
@misc{dcc7642d2f577a,
title = {Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center… — Europe PMC PMID:42459641},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42459641},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c7642d2f577a; sha256 d88a1f6f97dcedb1f163221cf70d198ef47bda941dc5aba90789dd39fc0447e3},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42459641. Agents can read the archived copy with the MCP tool read_document.